KR20190038914A - 오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법 - Google Patents

오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법 Download PDF

Info

Publication number
KR20190038914A
KR20190038914A KR1020197007454A KR20197007454A KR20190038914A KR 20190038914 A KR20190038914 A KR 20190038914A KR 1020197007454 A KR1020197007454 A KR 1020197007454A KR 20197007454 A KR20197007454 A KR 20197007454A KR 20190038914 A KR20190038914 A KR 20190038914A
Authority
KR
South Korea
Prior art keywords
dose
during
administered
regimen
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197007454A
Other languages
English (en)
Korean (ko)
Inventor
에리크 발스트룀
마리나 자펠리바 프라츠
알기르다스 요나스 카카리카 바이스코프
조셉 마이클 칸
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20190038914A publication Critical patent/KR20190038914A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197007454A 2016-08-15 2017-08-11 오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법 Ceased KR20190038914A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374986P 2016-08-15 2016-08-15
US62/374,986 2016-08-15
PCT/IB2017/054909 WO2018033841A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034140A Division KR20200136503A (ko) 2016-08-15 2017-08-11 오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법

Publications (1)

Publication Number Publication Date
KR20190038914A true KR20190038914A (ko) 2019-04-09

Family

ID=59901554

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207034140A Ceased KR20200136503A (ko) 2016-08-15 2017-08-11 오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법
KR1020197007454A Ceased KR20190038914A (ko) 2016-08-15 2017-08-11 오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207034140A Ceased KR20200136503A (ko) 2016-08-15 2017-08-11 오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법

Country Status (24)

Country Link
US (5) US11161909B2 (enExample)
EP (4) EP3497132B1 (enExample)
JP (2) JP6851391B2 (enExample)
KR (2) KR20200136503A (enExample)
CN (5) CN120053638A (enExample)
AU (2) AU2017311664C1 (enExample)
CA (2) CA3101514A1 (enExample)
CY (1) CY1123350T1 (enExample)
DE (1) DE202017007542U1 (enExample)
DK (2) DK3733712T3 (enExample)
ES (2) ES2821924T3 (enExample)
FI (1) FI3733712T3 (enExample)
HR (2) HRP20201388T1 (enExample)
HU (2) HUE063625T2 (enExample)
IL (4) IL302488B2 (enExample)
LT (2) LT3733712T (enExample)
MX (1) MX388593B (enExample)
PL (2) PL3733712T3 (enExample)
PT (2) PT3497132T (enExample)
RS (2) RS64541B1 (enExample)
RU (1) RU2749951C2 (enExample)
SI (2) SI3497132T1 (enExample)
TW (1) TWI752995B (enExample)
WO (1) WO2018033841A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3101514A1 (en) * 2016-08-15 2018-02-22 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
EP4028421A1 (en) * 2019-09-11 2022-07-20 Novartis AG Management of conditions other than multiple sclerosis in ofatumumab-treated patients
MX2022003010A (es) 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
US20230151106A1 (en) * 2020-04-09 2023-05-18 Novartis Ag OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG
EP4323000A1 (en) * 2021-04-14 2024-02-21 Novartis AG Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
JP2003529361A (ja) 2000-03-30 2003-10-07 アムジェン インコーポレイテッド ＣＤ２０／ＩｇＥレセプター様分子およびその使用
EA007958B1 (ru) 2000-08-03 2007-02-27 Терапеутик Хьюман Поликлоналз Инк. ТРАНСГЕННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГУМАНИЗИРОВАННЫЙ ЛОКУС Ig, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТРАНСГЕННЫХ ЖИВОТНЫХ
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
AR082436A1 (es) 2010-08-02 2012-12-05 Sanofi Aventis Us Llc Uso de teriflunomida para tratar la esclerosis multiple
JP2014506258A (ja) * 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規使用
AU2013200903B2 (en) * 2012-02-08 2015-05-14 Mcure Biosciences Inc. CDIM binding proteins and uses thereof
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
AU2013299557B2 (en) 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
JP2017514824A (ja) 2014-04-29 2017-06-08 テバ ファーマシューティカル インダストリーズ リミティド 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
CN106699886A (zh) 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
CA3101514A1 (en) 2016-08-15 2018-02-22 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
MX2022003010A (es) 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
EP4028421A1 (en) 2019-09-11 2022-07-20 Novartis AG Management of conditions other than multiple sclerosis in ofatumumab-treated patients
US20230151106A1 (en) 2020-04-09 2023-05-18 Novartis Ag OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG
EP4323000A1 (en) 2021-04-14 2024-02-21 Novartis AG Ofatumumab for treating multiple sclerosis in asian patients
IL310813A (en) 2021-08-16 2024-04-01 Novartis Ag OFATUMUMAB for the treatment of multiple sclerosis in children

Also Published As

Publication number Publication date
AU2020201112C1 (en) 2025-05-22
AU2020201112A1 (en) 2020-03-05
CN120053639A (zh) 2025-05-30
IL302488B2 (en) 2024-12-01
JP6851391B2 (ja) 2021-03-31
AU2017311664C1 (en) 2025-05-22
IL313932A (en) 2024-08-01
CN120053638A (zh) 2025-05-30
AU2017311664A1 (en) 2019-01-31
RU2019107146A3 (enExample) 2020-09-15
HRP20201388T1 (hr) 2020-11-27
HUE051948T2 (hu) 2021-03-29
CY1123350T1 (el) 2021-12-31
PT3733712T (pt) 2023-08-31
PL3497132T3 (pl) 2020-11-30
US12338290B2 (en) 2025-06-24
SI3733712T1 (sl) 2023-12-29
MX2019001860A (es) 2019-07-08
CN109641965A (zh) 2019-04-16
PT3497132T (pt) 2020-09-25
SI3497132T1 (sl) 2020-10-30
DK3733712T3 (da) 2023-08-21
IL302488A (en) 2023-06-01
EP4252847A2 (en) 2023-10-04
US20220081488A1 (en) 2022-03-17
CA3101514A1 (en) 2018-02-22
IL264804B (en) 2020-09-30
EP4252847A3 (en) 2023-11-15
EP4371611A2 (en) 2024-05-22
IL276890A (en) 2020-10-29
LT3497132T (lt) 2020-10-12
US20190177424A1 (en) 2019-06-13
RU2019107146A (ru) 2020-09-15
JP2020100630A (ja) 2020-07-02
WO2018033841A1 (en) 2018-02-22
FI3733712T3 (fi) 2023-08-22
DK3497132T3 (da) 2020-09-07
US20240317878A1 (en) 2024-09-26
US20240150485A1 (en) 2024-05-09
KR20200136503A (ko) 2020-12-07
AU2017311664B2 (en) 2020-01-02
EP4371611A3 (en) 2024-07-24
CA3030530C (en) 2021-02-23
RU2749951C2 (ru) 2021-06-21
CA3030530A1 (en) 2018-02-22
ES2821924T3 (es) 2021-04-28
US20250289902A1 (en) 2025-09-18
EP3733712B1 (en) 2023-05-24
EP3733712A1 (en) 2020-11-04
RU2021105514A (ru) 2021-04-19
EP3497132B1 (en) 2020-06-24
JP7198786B2 (ja) 2023-01-04
RS60807B1 (sr) 2020-10-30
RU2021105514A3 (enExample) 2022-02-08
HUE063625T2 (hu) 2024-01-28
TWI752995B (zh) 2022-01-21
IL276890B2 (en) 2023-10-01
CN120037367A (zh) 2025-05-27
DE202017007542U1 (de) 2022-07-19
LT3733712T (lt) 2023-09-11
CN120000782A (zh) 2025-05-16
RS64541B1 (sr) 2023-09-29
AU2020201112B2 (en) 2021-07-22
PL3733712T3 (pl) 2023-10-16
US11161909B2 (en) 2021-11-02
IL276890B1 (en) 2023-06-01
EP3497132A1 (en) 2019-06-19
IL302488B1 (en) 2024-08-01
JP2019511506A (ja) 2019-04-25
TW201808333A (zh) 2018-03-16
ES2954259T3 (es) 2023-11-21
HRP20230894T1 (hr) 2023-11-24
MX388593B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
US12338290B2 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
RU2782069C2 (ru) Схемы и способы лечения рассеянного склероза с применением офатумумаба
HK40101642A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40111448A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40032047A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40032047B (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40005527A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40005527B (en) Regimens and methods of treating multiple sclerosis using ofatumumab

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20190314

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190314

Comment text: Request for Examination of Application

PG1501 Laying open of application
A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20200324

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200403

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200828

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200403

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201126

PJ0201 Trial against decision of rejection

Patent event date: 20201126

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20200828

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20210727

Appeal identifier: 2020101002875

Request date: 20201126

J301 Trial decision

Free format text: TRIAL NUMBER: 2020101002875; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20201126

Effective date: 20210727

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20210727

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20201126

Decision date: 20210727

Appeal identifier: 2020101002875